Mutations of the p53 and ras genes in childhood t(1;19)-acute lymphoblastic leukemia

• Published in: Blood 1995-05, Vol.85 (9), p.2546-2552
• Main Authors: KAWAMURA, M, KIKUCHI, A, HAYASHI, Y, KOBAYASHI, S, HANADA, R, YAMAMOTO, K, HORIBE, K, SHIKANO, T, UEDA, K, HAYASHI, K, SEKIYA, T
• Format: Article
• Language: English
• Subjects: Adolescent; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Base Sequence; Biological and medical sciences; Child; Child, Preschool; Chromosomes, Human, Pair 1 - ultrastructure; Chromosomes, Human, Pair 19 - ultrastructure; Codon - genetics; Disease Progression; DNA Mutational Analysis; DNA, Neoplasm - genetics; Drug Resistance; Female; Frameshift Mutation; Genes, Immediate-Early; Genes, p53; Genes, ras; Hematologic and hematopoietic diseases; Humans; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis; Male; Medical sciences; Molecular Sequence Data; Neoplasm Recurrence, Local - genetics; Point Mutation; Polymerase Chain Reaction; Polymorphism, Single-Stranded Conformational; Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy; Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics; Translocation, Genetic; Treatment Failure
• ISSN: 0006-4971; 1528-0020
• DOI: 10.1182/blood.V85.9.2546.bloodjournal8592546

We have investigated the alterations of p53 and ras genes including H-, K-, and N-ras genes in 22 acute lymphoblastic leukemia (ALL) cases and five cell lines carrying t(1;19) by use of polymerase chain reaction (PCR)-single-strand conformation polymorphism (SSCP) analysis and direct sequencing. The mutations of the p53 gene were found in 2 of 20 t(1;19)-ALL cases at diagnosis (10%), all of 4 cases at relapse (100%), and 4 of the 5 cell lines (80%). Four of the five patients who died had missense mutations at codons 49, 177, 179, and 248. In cases examined sequentially, one had the same point mutation at codon 179 at both diagnosis and relapse, and another had the same p53 gene mutation at codon 240 both in leukemic cells at relapse and in a cell line derived at that time. The other case had no mutation at diagnosis but had the mutation at codon 177 at relapse and cell lines derived from blast cells at diagnosis, suggesting that a small number of leukemic cells with the p53 gene mutation at diagnosis might have escaped PCR-SSCP analysis. In cell lines, SCMC-L9 had three point mutations in the p53 gene at codons 175, 248, and 358, whereas SCMC-L10 had frame shift at codons 209-211. One case had a rare polymorphism at codon 11. We found only one mutation of the N-ras gene that was a 2-bp substitution of GGT(Gly) to GTC(Val) at codon 13 among 22 t(1;19)-ALL cases and five cell lines. This case showed no mutation of the p53 gene and has had a good course. These results suggest that in t(1;19)-ALL, mutations of the p53 and ras genes are infrequent at diagnosis and that p53 gene alterations may be associated with relapse phase or progression of t(1;19)-ALL.